Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 70Years
All Genders
NCT07185269

The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE

Led by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Updated on 2025-11-26

198

Participants Needed

1

Research Sites

162 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study will evaluate the effect and safety of 626 in patients with SLE

CONDITIONS

Official Title

The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able to understand protocol requirements and sign a written informed consent form
  • Male or female aged 18 to 70 years at consent
  • Body weight between 40 and 90 kg
  • Diagnosed with SLE at least 6 months before screening, confirmed by 2019 EULAR/ACR criteria
  • At screening, positive for either ANA titer ≥ 1:80 or anti-dsDNA antibody
  • SLE Disease Activity Index (SLEDAI-2K) score ≥ 6 with clinical score ≥ 4 at screening and baseline
  • Currently receiving at least one standard SLE medication: oral corticosteroid, antimalarial, or immunosuppressive agent
Not Eligible

You will not qualify if you...

  • Presence of mixed connective tissue disease or overlap syndrome with systemic sclerosis
  • Any medical or psychiatric condition that could compromise participation, including life-threatening illness
  • Active Hepatitis B, Hepatitis C, or HIV infection at screening
  • History of cancer
  • Active severe lupus nephritis within 2 months prior to baseline or kidney function with eGFR <30 mL/min/1.73m2 or protein:creatinine ratio >2.0 g/g

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China, 100730

Actively Recruiting

Loading map...

Research Team

Q

Qinghong Zhou

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

7

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here